Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation – Update on Methods

This presentation was given at the Reagan-Udall Foundation and Friends of Cancer Research COVID-19 Diagnostics Evidence Accelerator Parallel Analysis meeting by Vincent Lo Re from the University of Pennsylvania on behalf of the FDA Sentinel COVID-19 Coagulopathy workgroup. It includes updates to the study design previously presented on the June 5, 2020 meeting such as priority data sources, inclusions and exclusions within the cohort, and planned data elements.